AstraZeneca Reports 11 Percent Revenue Growth, Commits to USD 50 Bn US Expansion
For H1 2025, AstraZeneca’s total revenue rose 11 percent at constant exchange rates (CER) to USD 28.0 billion, driven by double-digit growth in both its oncology and biopharmaceuticals divisions.
AstraZeneca CEO Pascal Soriot | 29/07/2025 | By Dineshwori | 113
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy